GlassScriptPhysician profile
Phat Thuan Vo
NPI 1821519711
$8,859.76
in general payments reported to CMS, 2019-2025
33 companies · $1,669 in 2025
The $1,669 reported for 2025 was more than what 96% of Optometrist providers received nationally (typical 2025 total: $204).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $651 · 2020: $857 · 2021: $1,018 · 2022: $1,194 · 2023: $1,766 · 2024: $1,704 · 2025: $1,669.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $4,978 · Entertainment: $162.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $4,978.00 |
| Entertainment | $161.65 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Biotissue Holdings INC. | $1,457.75 | 2021-2025 | |
| Sun Pharmaceutical Industries INC. | $824.04 | 2019-2025 | Cequa |
| Novartis Pharmaceuticals Corporation | $791.98 | 2019-2023 | |
| Bausch & Lomb Americas INC. | $769.19 | 2022-2025 | Miebo, Xiidra, Vyzulta |
| Alcon Vision LLC | $528.32 | 2019-2025 | Clareon, Tryptyr, Eysuvis |
| Abbvie INC. | $431.73 | 2022-2025 | Vuity, Alphagan P, Lumigan |
| Johnson & Johnson Vision Care, INC. | $418.48 | 2019-2025 | |
| Oyster Point Pharma, INC. | $391.76 | 2022-2024 | Tyrvaya, Ryzumvi |
| Allergan, INC. | $367.60 | 2019-2022 | |
| Johnson & Johnson Surgical Vision, INC. | $345.31 | 2022-2025 | Tecnis Simplicity, Veritas Vision System, Tecnis Iol |
| Bausch & Lomb, A Division of Bausch Health US, LLC | $335.39 | 2019-2021 | |
| Kala Pharmaceuticals, INC. | $269.72 | 2021-2022 | |
| Tarsus Pharmaceuticals, INC. | $255.48 | 2024-2025 | Xdemvy |
| Harrow Eye, LLC | $203.99 | 2024-2025 | Vevye |
| Lumenis Be INC | $168.50 | 2023 | Optilight |
Show all 33 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Optos, INC. | $161.65 | 2023-2025 | Panoramic Ophthalmoscope, Oct Ophthalmoscope, Nfc-700 |
| Dompe US, INC. | $159.94 | 2021-2025 | Oxervate |
| Aerie Pharmaceuticals, INC. | $152.33 | 2019-2020 | |
| Rayner Intraocular Lenses Limited | $96.12 | 2023-2025 | Rayone Spheric, Rayone Emv, Rayone Aspheric |
| Rxsight INC | $92.53 | 2023-2025 | Rxsight Light Delivery Device (Ldd), Rxsight Injector Handpiece, Rxsight Injector Cartridge |
| Lkc Technologies, INC. | $88.85 | 2023 | |
| Glaukos Corporation | $87.14 | 2022-2025 | Idosetr |
| Ocular Therapeutix, INC. | $83.63 | 2023-2025 | Dextenza |
| Sight Sciences, INC. | $75.42 | 2025 | Omni Surgical System |
| Shire North American Group INC | $72.04 | 2019 | |
| Genzyme Corporation | $71.38 | 2022 | |
| Thea Pharma INC. | $41.92 | 2023-2024 | Iyuzeh |
| Eyevance Pharmaceuticals LLC | $32.14 | 2021-2022 | |
| Lensar, INC. | $18.93 | 2024 | Lensar Laser System |
| Eyepoint US, INC. | $18.41 | 2019 | |
| Astellas Pharma US INC | $17.72 | 2024 | Izervay |
| Menicon America INC | $16.67 | 2019 | |
| Tearlab Corp | $13.70 | 2022 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Phat Vo listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.